Compare ADMA Biologics Inc (ADMA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Sibanye Stillwater Ltd — how do they compare? ADMA Biologics Inc trades at $9.92 (market cap $2.22B), while Sibanye Stillwater Ltd trades at $10.76 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 3.4× ADMA Biologics Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SBSW | |
|---|---|---|
Market Cap | $2.22B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $21.12 |
52-Week Low | $7.60 | $7.27 |
Enterprise Value | $2.29B | $9.19B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Sibanye Stillwater (SBSW) trades at $10.67, up 0.28% with a bullish technical signal despite recent earnings misses. The stock shows attractive valuation metrics with P/E of 4.76 and P/S of 0.94, though profitability remains challenged with negative net income margin of -3.99%. Recent news highlights significant price volatility and mixed analyst views on valuation.
The outlook suggests potential upside to the $14.25 consensus price target, supported by projected cash flow improvement in 2025. Key risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Institutional sentiment leans bullish with 43% buy ratings, but investors should monitor execution on debt reduction targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
